본문 바로가기
KERD
논문KCI 등재

Oral Administration of β-Glucan and Lactobacillus plantarum Alleviates Atopic Dermatitis-Like Symptoms

3

조회

0

다운로드

2

인용

0

참고문헌

키워드

주제분류생물학

초록

Atopic dermatitis (AD) is a chronic inflammatory skin disease of mainly infants and children. Currently, the development of safe and effective treatments for AD is urgently required. The present study was conducted to investigate the immunomodulatory effects of yeast-extracted β-1,3/1,6-glucan and/or Lactobacillus plantarum (L. plantarum) LM1004 against AD-like symptoms. To purpose, β-1,3/1,6-glucan and/or L. plantarum LM1004 were orally administered to AD-induced animal models of rat (histamine-induced vasodilation) and mouse (pruritus and contact dermatitis) exhibiting different symptoms of AD. We then investigated the treatment effects on AD-like symptoms, gene expression of immune-related factors, and gut microbiomes. Oral administration of β-1,3/1,6-glucan (0.01 g/kg initial body weight) and/or 2 × 1012 cells/g L. plantarum LM1004 (0.01 g/kg initial body weight) to ADinduced animal models showed significantly reduced vasodilation in the rat model, and pruritus, edema, and serum histamine in the mouse models (p < 0.05). Interestingly, β-1,3/1,6- glucan and/or L. plantarum LM1004 significantly decreased the mRNA levels of Th2 and Th17 cell transcription factors, while the transcription factors of Th1 and Treg cells, galactin-9, filaggrin increased, which are indicative of enhanced immunomodulation (p < 0.05). Moreover, in rats with no AD induction, the same treatments significantly increased the relative abundance of phylum Bacteroidetes and the genus Bacteroides. Furthermore, bacterial taxa associated with butyrate production such as, Lachnospiraceae and Ruminococcaceae at family, and Roseburia at genus level were increased in the treated groups. These findings suggest that the dietary supplementation of β-1,3/1,6-glucan and/or L. plantarum LM1004 has a great potential for treatment of AD as well as obesity in humans through mechanisms that might involve modulation of host immune systems and gut microbiota.

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease of mainly infants and children. Currently, the development of safe and effective treatments for AD is urgently required. The present study was conducted to investigate the immunomodulatory effects of yeast-extracted β-1,3/1,6-glucan and/or Lactobacillus plantarum (L. plantarum) LM1004 against AD-like symptoms. To purpose, β-1,3/1,6-glucan and/or L. plantarum LM1004 were orally administered to AD-induced animal models of rat (histamine-induced vasodilation) and mouse (pruritus and contact dermatitis) exhibiting different symptoms of AD. We then investigated the treatment effects on AD-like symptoms, gene expression of immune-related factors, and gut microbiomes. Oral administration of β-1,3/1,6-glucan (0.01 g/kg initial body weight) and/or 2 × 1012 cells/g L. plantarum LM1004 (0.01 g/kg initial body weight) to ADinduced animal models showed significantly reduced vasodilation in the rat model, and pruritus, edema, and serum histamine in the mouse models (p < 0.05). Interestingly, β-1,3/1,6- glucan and/or L. plantarum LM1004 significantly decreased the mRNA levels of Th2 and Th17 cell transcription factors, while the transcription factors of Th1 and Treg cells, galactin-9, filaggrin increased, which are indicative of enhanced immunomodulation (p < 0.05). Moreover, in rats with no AD induction, the same treatments significantly increased the relative abundance of phylum Bacteroidetes and the genus Bacteroides. Furthermore, bacterial taxa associated with butyrate production such as, Lachnospiraceae and Ruminococcaceae at family, and Roseburia at genus level were increased in the treated groups. These findings suggest that the dietary supplementation of β-1,3/1,6-glucan and/or L. plantarum LM1004 has a great potential for treatment of AD as well as obesity in humans through mechanisms that might involve modulation of host immune systems and gut microbiota.

참고문헌 (80)

  1. Leung DY, "New insights into atopic dermatitis", J. Clin. Invest, 113, pp.651~657 (2004)
  2. Leung DY, "Pathogenesis of atopic dermatitis", J. Allergy Clin. Immunol, 104, pp.99~108 (1999)
  3. Sano Y, "Thymic stromal lymphopoietin expression is increased in the horny layer of patients with atopic dermatitis", Clin. Exp. Immunol, 171, pp.330~337 (2013)
  4. Soumelis V, "Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP", Nat. Immunol, 3, pp.673~680 (2002)
  5. Noda S, "The translational revolution and use of biologics in patients with inflammatory skin diseases", J. Allergy Clin. Immunol, 135, pp.324~336 (2015)
  6. Young CA, "Loss of epidermal AP1 transcription factor function reduces filaggrin level, alters chemokine expression and produces an ichthyosis-related phenotype", Cell Death Dis, 8, pp.e2840~ (2017)
  7. Cooper KD, "Atopic dermatitis : recent trends in pathogenesis and therapy", J. Invest. Dermatol, 102, pp.128~137 (1994)
  8. Sidbury R, "Old, new, and emerging therapies for atopic dermatitis", Dermatol. Clin, 18, pp.1~11 (2000)
  9. Report of a joint FAO, "WHO expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria", 2001
  10. Klein G, "Taxonomy and physiology of probiotic lactic acid bacteria", Int. J. Food Microbiol, 41, pp.103~125 (1998)
  11. Gibson GR, "Dietary modulation of the human colonic microbiota : introducing the concept of prebiotics", J. Nutr, 125, pp.1401~1412 (1995)
  12. Kim YH, "Probiotics, prebiotics, synbiotics and human health", BT. News, 23, pp.17~22 (2016)
  13. Delaney B, "Beta-glucan fractions from barley and oats are similarly antiatherogenic in hypercholesterolemic Syrian golden hamsters", J. Nutr, 133, pp.468~475 (2003)
  14. Babicek K, "Toxicological assessment of a particulate yeast(1, 3", 1, 6)beta-D-glucan in rats, 2007, pp.45, 1719~1730
  15. 김수철, "베타글루칸 함량이 높은 큰느타리버섯 선발을 위한 SCAR marker 개발", 한국버섯학회지, 13(1), pp.79~83 (2015), 한국버섯학회
  16. Kim JH, "Production of high molecular weight pullulan by Aureobasidium pullulans using glucosamine", Biotechnol. Lett, 22, pp.987~990 (2000)
  17. Kraus J, "Antitumor activity of cell wall β-1, 3", 1, 6-glucans from Phytophthora species, 1992, pp.58, 39~42
  18. Mercenier A, "Probiotics as biotherapeutic agents : present knowledge and future prospects", Curr. Pharm. Des, 9, pp.175~191 (2003)
  19. Prescott SL, "Clinical effects of probiotics are associated with increased interferon-gamma responses in very young children with atopic dermatitis", Clin. Exp. Allergy, 35, pp.1557~1564 (2005)
  20. Peng GC, "The efficacy and safety of heatkilled Lactobacillus paracasei for treatment of perennial allergic rhinitis induced by house-dust mite", Pediatr. Allergy Immunol, 16, pp.433~438 (2005)
  21. 김인성, "Effect of oral administration of b-glucans derived from Aureobasidium pullulans SM-2001 in model mice and rat with atopic dermatitis-like phenotypes", Food Science and Biotechnology, 27(4), pp.1185~1192 (2018), 한국식품과학회[DOI]
  22. 서형필, "Aureobasidium pullulans SM-2001에 의한 β-1,3", 1,6-글루칸의 생산, 2002, pp.17(4), 376~380[DOI]
  23. Ishiguro K, "Effects of conjugated linoleic acid on anaphylaxis and allergic pruritus", Biol. Pharm. Bull, 25, pp.1655~1657 (2002)
  24. Katayama S, "A new method for extraction of extravasated dye in the skin and the influence of fasting stress on passive cutaneous anaphylaxis in guinea pigs and rate", Microbiol. Immunol, 22, pp.89~101 (1978)
  25. Chomczynski P, "Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction", Anal. Biochem, 162, pp.156~159 (1987)
  26. Hwang JS, "Modulation of experimental atopic dermatitis by topical application of Gami-Cheongyeul-Sodok-Eum", BMC Complement. Altern. Med, 13, pp.312~ (2013)
  27. van Hamburg JP, "Enforced expression of GATA3 allows differentiation of IL-17producing cells, but constrains Th17-mediated pathology", Eur. J. Immunol, 38, pp.2573~2586 (2008)
  28. Kwon HK, "Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders", Proc. Natl. Acad. Sci. USA, 107, pp.2159~2164 (2010)
  29. Chabot S, "Regulation of galectin-9 expression and release in Jurkat T cell line cells", Glycobiology, 12, pp.111~118 (2002)
  30. Shin JH, "A multistrain probiotic formulation attenuates skin symptoms of atopic dermatitis in a mouse model through the generation of CD4+Foxp3+ T cells", Food Nutr. Res, 60, pp.32550~ (2016)
  31. Ohtsuka E, "Roles of mast cells and histamine in mosquito bite-induced allergic itch-associated responses in mice", Jpn. J. Pharmacol, 86, pp.97~105 (2001)
  32. Eisen HN, "Studies of hypersensitivity to low molecular weight substances, II. Reactions of some allergenic substituted dinitrobenzenes with cysteine or cystine of skin proteins", J. Exp. Med, 98, pp.533~549 (1953)
  33. Matsuda H, "Anti-allergic effects of cnidii monnieri fructus(dried fruits of Cnidium monnieri)and its major component, osthol", Biol. Pharm. Bull, 25, pp.809~812 (2002)
  34. Yoon SH, "Introducing EzBioCloud : A taxonomically united database of 16S rRNA and whole genome assemblies", Int. J. Syst. Evol. Microbiol, 67, pp.1613~1617 (2017)
  35. Derakhshani H, "An extended single index multiplexed 16S rRNA sequencing for microbial community analysis on MiSeq Illumina platforms", J. Basic Microbiol, 56, pp.321~326 (2016)
  36. Duncan DB, "Multiple range and multiple F tests", Biometrics, 11, pp.1~42 (1955)
  37. Niki T, "Galectin-9 is a high affinity IgEbinding lectin with anti-allergic effect by blocking IgEantigen complex formation", J. Biol. Chem, 284, pp.32344~32352 (2009)
  38. Seki M, "Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis", Clin. Immunol, 127, pp.78~88 (2008)
  39. 류지철, "消風散 추출물이 수동 피부 아나팔락시스 (1형 알러지 피부염)에 미치는 효과", 한방안이비인후피부과학회지, 22(3), pp.1~10 (2009), 대한한방안이비인후피부과학회
  40. Rothschild AM, "Reversible rat mesenteric mast cell swelling caused by vagal stimulation or sham-feeding", Agents Actions, 34, pp.295~301 (1991)
  41. Inagaki N, "Inhibition of vascular permeability increase in mice, An additional anti-allergic mechanism of glucocorticoids", Int. Arch. Allergy Appl. Immunol, 87, pp.254~259 (1988)
  42. Byun DG, "Influence of cytokines on the development of T cell subsets", Pediatr. Allergy Respir. Dis, 6, pp.20~32 (1996)
  43. Haw CR, "Skin allergy", J. Kyung Hee Univ. Med. Cent, 12, pp.108~116 (1996)
  44. Bunker CB, "Vascular responses to histamine at low temperatures in normal digital skin and Raynaud’s phenomenon", Agents Actions, 33, pp.197~199 (1991)
  45. Powrie F, "Cytokine regulation of T-cell function : potential for therapeutic intervention", Trends Pharmacol. Sci, 14, pp.164~168 (1993)
  46. Kim MS, "Forsythia fructus inhibits the mast-cell-mediated allergic inflammatory reaction", Inflammation, 27, pp.129~135 (2003)
  47. Sugimoto Y, "Effects of histamine H1 receptor antagonists on Compound 48", 80induced scratching behavior in mice, 1998, pp.351, 1~5
  48. Shinmei Y, "Effect of Brazilian propolis on scratching behavior induced by Compound 48", 80 and histamine in mice, 2004, pp.4, 1431~1436
  49. Nagai H, "Immunoglobulin E production in mice by means of contact sensitization with a simple chemical, hapten", J. Allergy Clin. Immunol, 100, pp.39~44 (1997)
  50. Ueda Y, "Effects of prednisolone on the cutaneous reaction and skin barrier function in mice treated with a hapten", Biol. Pharm. Bull, 26, pp.618~621 (2003)
  51. Watanabe C, "Inhibitory mechanisms of glycoprotein fraction derived from Miscanthus sinensis for the immediate phase response of an IgE-mediated cutaneous reaction", Biol. Pharm. Bull, 22, pp.26~30 (1999)
  52. Romagnani S, "T-cell subsets(Th1 versus Th2)", Ann. Allergy Asthma Immunol, 85, pp.9~18 (2000)
  53. Belardelli F, "Role of interferons and other cytokines in the regulation of the immune response", APMIS, 103, pp.161~179 (1995)
  54. Kidd P, "Th1", Th2 balance : the hypothesis, its limitations, and implications for health and disease, 2003, pp.8, 223~246
  55. Romagnani S, "The role of lymphocytes in allergic disease", J. Allergy Clin. Immunol, 105, pp.399~408 (2000)
  56. Stone KD, "IgE, mast cells, basophils, and eosinophils", J. Allergy Clin. Immunol, 125, pp.73~80 (2010)
  57. Korn T, "Th17 cells : effector T cells with inflammatory properties", Semin. Immunol, 9, pp.362~371 (2007)
  58. Lubberts E, "Requirement of IL-17 receptor signaling in radiation-resistant cells in the joint for full progression of destructive synovitis", J. Immunol, 175, pp.3360~3368 (2005)
  59. Palomeres O, "Role of Treg in immune regulation of allergic diseases", Eur. J. Immunol, 40, pp.1232~1240 (2010)
  60. Dai SY, "Galectin-9 induces maturation of human monocyte-derived dendritic cells", J. Immunol, 175, pp.2974~2981 (2005)
  61. de Kivit S, "Galectin-9 induced by dietary synbiotics is involved in suppression of allergic symptoms in mice and humans", Allergy, 67, pp.343~352 (2012)
  62. Furue M, "Gene regulation of filaggrin and other skin barrier proteins via aryl hydrocarbon receptor", J. Dermatol. Sci, 80, pp.83~88 (2015)
  63. Murray IA, "Expression of the aryl hydrocarbon receptor contributes to the establishment of intestinal microbial community structure in mice", Sci. Rep, 6, pp.33969~ (2016)
  64. Furue M, "Atopic dermatitis : immune deviation, barrier dysfunction, IgE autoreactivity and new therapies", Allergol. Int, 66, pp.398~403 (2017)
  65. Kim HJ, "Effects of Lactobacillus rhamnosus on allergic march model by suppressing Th2, Th17, and TSLP responses via CD4+ CD25+ Foxp3+ Tregs", Clin. Immunol, 153, pp.178~186 (2014)
  66. Gantner BN, "Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor", J. Exp. Med, 197, pp.1107~1117 (2003)
  67. Thornton BP, "Analysis of the sugar specificity and molecular location of the beta-Glucan-binding lectin site of complement receptor type 3(CD11b", CD18), 1996, pp.156, 1235~1246
  68. Sugiyama A, "Oral administration of Paramylon, a β-1, 3-DGlucan isolated from Euglena gracilis Z inhibits development of atopic dermatitis-like skin lesions in NC", Nga mice, 2010, pp.72, 755~763
  69. Perdigon G, "Interaction of lactic acid bacteria with the gut immune system", Eur. J. Clin. Nutr, 56, pp.21~26 (2002)
  70. Harata G, "Differentiated implication of Lactobacillus GG and L, gasseri TMC0356 to immune responses of murine Peyer's patch", Microbiol. Immunol, 53, pp.475~480 (2009)
  71. Liu M, "Regulatory roles of IL-12, IL-4, and IFN-gamma on IgE synthesis in atopic patients", Chin. Med. J, 112, pp.550~553 (1999)
  72. De Filippo C, "Impact of diet in shaping gut microbiota revealed by a comparative study in children from europe and rural Africa", Proc. Natl. Acad. Sci. USA, 107, pp.14691~14696 (2010)
  73. Trompette A, "Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis", Nat. Med, 20, pp.159~166 (2014)
  74. Vulevic J, "Influence of galacto-oligosaccharide mixture(B-GOS)on gut microbiota, immune parameters and metabonomics in elderly persons", Br. J. Nutr, 114, pp.586~595 (2015)
  75. Song Y, "Alistipes onderdonkii sp, nov. and Alistipes shahii sp. nov., of human origin", Int. J. Syst. Evol. Microbiol, 56, pp.1985~1990 (2006)
  76. Bhute SS, "Gut microbial diversity assessment of indian type-2-diabetics reveals alterations in eubacteria, archaea, and eukaryotes", Front. Microbiol, 8, pp.214~ (2017)
  77. Duncan SH, "Lactate-utilizing bacteria, isolated from human feces, that produce butyrate as a major fermentation product", Appl. Environ. Microbiol, 70, pp.5810~5817 (2004)
  78. Anand S, "Comparative in silico analysis of butyrate production pathways in gut commensals and pathogens, Front", Front. Microbiol, 7, pp.1945~ (2016)
  79. Jin H, "Animal models of atopic dermatitis", J. Invest. Dermatol, 129, pp.31~40 (2009)
  80. Martel BC, "Traslational animal models of atopic dermatitis for preclinical studies", Yale J. Biol. Med, 90, pp.389~402 (2017)

관련 논문AI추천

이 간행물의 다른 논문 (8건)